Investors



SEC Filings

Filing date Form Description Filing Group View
6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
EX-101.INS - EX-101.INS View HTML
SC 13D/A

An amendment to a SC 13D filing

3,4,5
View HTML
6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
View HTML
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
View HTML
SC 13G

A statement of beneficial ownership of common stock by certain persons

3,4,5
View HTML
CT ORDER

CT ORDER

Other
View HTML
6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
EX-101.INS - EX-101.INS View HTML
6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML

Copyright Morningstar







© 2018 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
Macrilen is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V13 01/2018

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200
info@strongbridgebio.com

Privacy Statement
Compliance Program